|Year : 2018 | Volume
| Issue : 5 | Page : 123-128
Molecular insights turning game for management of ependymoma: A review of literature
Ajay Sasidharan, Rahul Krishnatry
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
|Date of Web Publication||30-Oct-2018|
Dr. Rahul Krishnatry
Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra
Source of Support: None, Conflict of Interest: None
Molecular biology of ependymoma is being extensively studied in recent years, providing insights into newer therapeutic strategies. The different anatomic subgroups of ependymoma, namely supratentorial, posterior fossa (PF), and spinal, pose entirely different clinical behavior and prognosis. Recently, nine molecular subgroups of ependymoma have been identified, one of which has been incorporated into the WHO classification. Further understanding of the molecular biology of ependymoma is vital to expand its clinical utility. Here, we performed a review of the literature on the molecular biology of ependymoma. Therapeutic avenues include: (1) targeted agents against – (a) chromothripsis-induced nuclear factor-kappa beta signaling, (b) gene silencing by DNA methylation, (c) increased telomerase activity, and (d) microRNA and (2) de-escalating treatment in good prognostic subgroup such as PFB. The prognostic value of different chromosomal gain or loss is being better understood and may serve as prognostic signatures in future. Faster adoption of molecular classification into clinical practice requires simpler identification techniques using immunohistochemical surrogates for molecular subgroups, for example, cell adhesion molecule L1 for v-rel reticuloendotheliosis viral oncogene homolog A (RELA) fusion, laminin subunit alpha 2, tenascin-C, and neural epidermal growth factor-like 2 for PFA and PFB. Identification of poor prognostic markers such as RELA fusion and PFA has necessitated future research impetus to be directed to find more efficacious treatment approach in these groups.
Keywords: Biology, ependymoma, molecular, subgroups
|How to cite this article:|
Sasidharan A, Krishnatry R. Molecular insights turning game for management of ependymoma: A review of literature. Cancer Transl Med 2018;4:123-8
|How to cite this URL:|
Sasidharan A, Krishnatry R. Molecular insights turning game for management of ependymoma: A review of literature. Cancer Transl Med [serial online] 2018 [cited 2019 Jan 16];4:123-8. Available from: http://www.cancertm.com/text.asp?2018/4/5/123/244521
| Introduction|| |
Ependymoma constitutes approximately 10% of pediatric brain tumors and is the third most common tumor after low-grade glioma and medulloblastoma. As per the referral pattern from four major tertiary cancer care centers in India, it is the fourth most common after astrocytoma, medulloblastoma, and craniopharyngioma. In our institute, ependymomas constitute 19.1% of pediatric brain tumors.
Median age of presentation of ependymoma is 2.4 years, and there is a slight male preponderance. Most pediatric ependymomas are intracranial with 80% of them occurring in the posterior fossa (PF). In adults, about 66% occur in the spinal cord and > 50% of the intracranial ependymomas are supratentorial (ST).
Surgery is the primary mode of treatment for ependymoma with gross total resection (GTR) or maximal safe resection being the most important prognostic factor. Adjuvant radiotherapy is the current standard of care in high-grade (II or III) ependymoma. Adjuvant radiotherapy decreases local recurrence following either GTR or subtotal resection (STR).,, The event-free survival (EFS) and overall survival (OS) at 5 years is 80% and 90% with GTR versus 40% and 50% with STR respectively., The EFS and OS at 10 years is 45% and 60% with GTR and 25% and 30% with STR. Adjuvant chemotherapy, as a strategy to avoid radiotherapy in young children (below 5 years of age), in SIOP study has shown an inferior survival rate, with 4 years EFS and OS rate of 22% and 59%, respectively, irrespective of the extent of surgical resection. Another study by UKCCSG/SIOP on adjuvant chemotherapy in children < 3 years with intracranial ependymoma showed an EFS of 44%. In comparison, adjuvant radiotherapy in children < 3 years has shown EFS of 68%. Hence, the role of chemotherapy remains inconclusive in young children with ependymoma.
| Understanding the Biology|| |
The biology of ependymoma has remained an enigma for clinicians. Despite the similar histology and grade, ependymoma behaves differently in different age groups and with respect to location of the tumor. Prognosis of ependymoma is positively associated with increasing age of the patient. Infants have a poorer five-year survival of 40%–50% compared to adults who have a better five-year survival of 80%–90%. ST ependymomas have a better prognosis compared to PF ependymomas that are more common in children. Whether these disparities in survival is due to the poorer resectability of PF lesions or lesser use of adjuvant radiotherapy in very young children or due to underlying biology was not well understood.
The 2007 WHO classification, classifying ependymoma into three grades, is found not useful as a robust prognostic classification, owing to poor interobserver variability between Grade II and III ependymoma, with high concordance rate of 69%, between pathologists., Grade I ependymomas, showing good prognosis predominantly in adults, includes myxopapillary ependymoma which usually arises in spinal cord and subependymoma which can occur in all three compartments. Grade II and III ependymomas are called classic and anaplastic ependymomas but are difficult to distinguish from each other histologically. Moreover, the utility of distinguishing between Grade II and III as a robust prognostic marker is not seen in all clinical settings.
Recently, nine molecular subgroups of ependymoma were identified in a large cohort of 500 tumors, and they outperform the current histological classification in associating clinical condition with the outcome. The molecular subgroups can be categorized based on their location – ST, PF, and spine. The new consensus on management of intracranial ependymoma recognizes that the treatment decisions for ependymoma should not be based on histopathological characteristics alone and that the molecular classification should be a component of any future clinical trial. Meanwhile, the 2016 update for the WHO classification of central nervous system tumors has accepted one genetically defined subtype: ependymoma, v-rel reticuloendotheliosis viral oncogene homolog A (RELA) fusion-positive.
| Understanding the Molecular Biology of Ependymomas|| |
Fusion of genes through chromothripsis
Chromothripsis is the phenomenon by which thousands of clustered chromosomal rearrangements occur in a single event, in localized and confined genomic regions, and in one or a few chromosomes. The chromothripsis phenomenon opposes the conventional theory that cancer is the gradual acquisition of genomic rearrangements and somatic mutations over time and was first observed while sequencing the genome of a chronic lymphocytic leukemia patient. Single nucleotide variations, insertions and deletions, or focal (< 5 genes) copy number alterations are rare in ependymomas, but structural variations (SVs) are detected relatively frequently in ST ependymomas. Using a technique called “clipping reveals structure,” the ST ependymomas have shown SVs clustered within 11q12.1–q13.3, an oscillating copy number state characteristic of chromothripsis. Although the chromothripsis region differed among tumor, most (70%) shared a common region in which the reordered chromosome fragments fused a poorly characterized gene-chromosome 11 open reading frame 95 (C11orf95) to RELA, the principal effectors of canonical nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB) signaling. The C11orf95-RELA fusion protein translocates spontaneously into the nucleus and activates.
NF-kB genes, and rapidly transforms neural stem cells to ependymal stem cells. NF-kB upregulation leads to increase in antiapoptotic factors. Most of the ST ependymomas harbor C11orf95-RELA fusion and can be identified by fluorescence in situ hybridization, however, in infants, YAP1 fusion (a transcriptional coactivator) is enriched.
Gene silencing by DNA methylation
DNA methylation is an epigenetic alteration caused by addition of methyl groups to cytosine base, changing the activity of the DNA segment without changing the sequence. It is mediated by DNA methyltransferase enzyme which transfers methyl group to cytosine, found within cytosine–phosphate–guanine dinucleotides (CpG), to form 5-methylcytosine. “CpG island methylator phenotype” has been extensively studied in colorectal cancer and has been identified in other cancers including gliomas. Hypermethylation causes gene silencing and decreases the expression of a number of tumor suppressor genes. ST and spinal pediatric ependymomas have hypermethylated phenotype leading to expression changes in genes involved in DNA repair and regulation of inflammation, namely, c-Jun N-terminal kinases pathway and peroxisome proliferator-activated receptor gamma. The data suggest that hypermethylation-induced epigenetic gene silencing is an important mechanism in the pathogenesis of ST and spinal ependymomas. However, in PF ependymoma, CpG-island (CpGi) hypermethylation has been identified; they are targeted by polycomb repressor comple × 2 (PRC2), containing enhancer of zeste homolog 2 (EZH2) which causes trimethylation of lysine 27 on histone H3 protein subunit (H3K27 me3) analogous to H3K27M-mutant gliomas, resulting in lowered H3K27 me3 in ependymomas with CpGi methylation. This had led to division of PF ependymoma into two subgroups: PFA and PFB, with PFA having relatively more CpGi hypermethylation compared to PFB. Beyond the CpGi regions, a global hypomethylation is evident in PFA tumors. PFA ependymoma has a worse prognosis than PFB across the entire age spectrum, and frequently relapse even after GTR and adjuvant radiation therapy. PFA patients are usually younger children, while PFB affects older children and young adults with none below 5 years of age. A vast majority of children under the age of 10 are PFA ependymoma, with a 50:50 split in adolescence, and only 15% of adult PF ependymoma being PFA subtype. In a population-based study, the 10 years OS in children < 3 years of age was 61% with GTR and 38.2% and 35% with STR and biopsy, respectively. The patients with PFB undergoing GTR have an excellent 10-year OS of 90%. Even without “upfront postsurgery external beam radiation,” this group shows a good OS, with successful salvage of relapse with radiation.
Increased telomerase activity
Telomeres are repetitive nucleotide sequence of TTAGGG, with complementary AATCCC, with single-strand TTAGGG overhang. This prevents DNA ends being recognized as DNA breaks. Telomeres of proliferating cells become shorter and shorter with ongoing cell division synonymous to cellular clock to aging, till they become dysfunctional, resulting in higher genomic instability and growth arrest. Telomere maintenance is one of the hallmarks of cancer. Human telomerase reverse transcriptase (hTERT) is essential for telomerase production and telomere maintenance. There is a correlation between MIB-1 proliferative index of > 12% and tumor grade, as 63% Grade 2 ependymomas and 11% Grade 3 ependymomas are hTERT negative. Correlating hTERT expression and DNA damage (¥H2AX as surrogate) with outcome in ependymoma has shown 5-year progression-free survival (PFS) and OS of 69±15% and 100%, respectively, in hTERT(−)/¥H2AX(+) patients versus 17%±8% and 22%±9%, respectively, in hTERT(+)/¥H2AX(−) patients. Telomerase enzymatic activity can serve to subgroup PF ependymoma, particularly the PFA group, into better and worse prognosis groups.
Chromosome gain or loss
The single molecular marker that has repeatedly shown an association with unfavorable outcome is gain of chromosome arm 1q, particularly in PF ependymomas of children. Chromosome 1q gain alone can be seen in up to 24% of pediatric ependymomas and 8% of adult ependymomas. Two studies have shown that “1q gain” is an independent prognostic factor in determining PFS,, with one of these studies showing its correlation with OS also. The most common genetic abnormality seen in ependymomas includes 6q loss and 5p gain, seen in about 60% and 40% of the cases, respectively. Prognostic value regarding 6q loss and 5p gain is not yet conclusive. Losses at 22q are frequently seen in NF2 associated intramedullary spinal ependymomas. Gain of dual phosphatase specific locus 12 in chromosome 1q, epidermal growth factor receptor (EGFR) in chromosome 7p, and hTERT in chromosome 5p have been identified in ependymomas. EGFR overexpression in ependymomas is seen not only due to chromosomal gain or gene amplification but other factors as well. Tumor protein-53 (TP53) gene is located in short arm of chromosome 17. Amplification of mouse double minute-2 homolog (MDM2) in chromosome 12 results in inhibition of TP53 in ependymomas, resulting in tumorigenesis. Other gains frequently seen are of ARHGEF5 gene at 7q and HOXC4 gene at 12q.
MicroRNAs (miRNAs) are small noncoding RNAs that have no protein-coding capacity and act by blocking translation of messenger RNA (mRNA), and thus regulate gene expression. High-grade ependymomas have been shown to have increased levels of miRNA expression. miRNA expression profiling has shown that ependymomas of different locations exhibit different miRNA profile. miRNA-203 (located in chromosome 14q32) downregulation is strongly associated with “time to relapse” in ependymoma. Upregulation of other miRNAs located in 14q32, such as miRNA-432, miR-411, miR-376a, miR-381, and miR-487b, was associated with lower relapse-free probability. miRNA 29a/c has been found to be a key regulator of laminin subunit alpha 2 (LAMA2) expression seen in PF ependymoma. Therefore, miRNAs seem to be an additional promising candidate as a prognostic marker in ependymoma.
| Immunohistochemistry Surrogate for Molecular Subgroups|| |
Most of the molecular testing in ependymomas is beyond the routine facilities available with usual pathology laboratories across the world. If something as simple as immunohistochemistry (IHC) can find a good surrogate for current complex molecular information, then it would be practically feasible to incorporate molecular information in routine clinical practice.
RELA fusion leads to an increased expression of neural cell adhesion molecule L1 (L1CAM) protein, and there is a high concordance of predicting RELA fusion using L1CAM IHC. Immunohistochemical expression of LAMA2 and neural epidermal growth factor-like 2 may serve as markers for PFA and PFB tumors, respectively, while high tenascin-C expression can be related to PFA tumors. The pediatric ependymoma protein database has identified > 5000 proteins and > 25,000 peptides for every analyzed sample of ependymoma. Identification of newer and more specific biomarkers of different molecular subgroups is hoped to bring about a radical change in the way ependymoma is evaluated.
| Potential Therapeutic Strategies in Ependymoma|| |
In ependymoma, a chemoresistant tumor, surgery and adjuvant radiotherapy is the standard of care. In view of excellent prognosis, adjuvant radiotherapy may be avoided in PFB tumors after maximal safe resection. Among chemotherapeutic drugs, only bolus 5-FU has shown some antitumor activity and was tested in recurrent pediatric ependymoma though the response was not very promising. BCL-2 (antiapoptotic) inhibition is being tested as a potential therapeutic approach in the light of it being significantly induced by C11orf95-RELA fusion protein. In a study targeting the JAK-STAT pathway, associated with apoptosis, STAT3 inhibitor WP1066 molecule has shown to decrease BCL-2, although the reduction in another antiapoptotic protein “survivin” also occurred, which correlated with apoptosis in the ependymal cells. Pediatric ependymomas are more aggressive tumors, with most of them located in PF. Epigenetic modifiers, inhibiting PRC2 using small molecule inhibitors of EZH2 such as 3-deazaneplanocin A (DZNep), decitabine (DAC), and GSK343, could be potential therapeutic target agents in PFA. The FDA approved decitabine (DNA methylation inhibitor) has shown significant antineoplastic effect under in vitro culture condition using cells derived from PFA patient and may serve as a potential therapeutic drug for these tumors in future. DNA methylation inhibitors have been approved for use in leukemia (5-azacytidine and deoxy analog of 5-azacytidine). Vorinostat, a histone deacetylase inhibitor, has shown in vitro to induce differentiation in the ependymal stem cells. Telomerase inhibition using MST-312 in in vitro cell lines increased DNA damage (¥H2AX expression) and decreased proliferative index (MIB-1) with half of the cells showing increased apoptosis (cleaved caspase 3), suggesting of a future promise as telomerase inhibition-based therapy. EGFR inhibitors AEE788 and gefitinib have shown reduction in proliferation and survival of ependymoma stem cell lines. Orally administered AEE788 improved survival in mice bearing ependymoma stem cell-driven orthotopic xenografts, from 56 to 63 days (P = 0.06). Phase I clinical trial of gefitinib in refractory pediatric solid tumors established a maximum tolerated dose of gefitinib as 400 mg/m2/day. In the study, one patient with ependymoma developed intratumoral bleeding at a dose of 500 mg/m2/day on the 18th day of treatment. A Phase II study comparing erlotinib (85 mg/m2/day) versus etoposide in refractory pediatric ependymoma was stopped after interim analysis due to the futility of efficacy. None of the patients in the erlotinib arm had an objective response, whereas some patients in the etoposide arm responded to the treatment (NCT01032070). Combining EGFR targeting agents with radiotherapy seems to be a potential therapeutic option. In a preclinical study with 9 pediatric ependymoma xenografts, 5 cases (55.5%) showed complete response and 4 cases (44.5%) showed partial response when treated with 1 Gy of irradiation followed by gefitinib (100 mg/kg for 5 consecutive days). However, Phase I or II clinical studies of EGFR inhibitors with radiotherapy are lacking. MDM2 inhibition using low-dose actinomycin-D has shown p53 reactivation at RNA, protein, and functional levels in preclinical high-risk ependymoma models. Antisense miRNAs, which are potent oligonucleotides targeted against overexpressed miRNA and replacement of loss-of-function miRNAs, are novel therapeutic strategies which are yet to be explored in ependymoma.
| Conclusion|| |
Prognostication based on molecular subgroups will help in tailoring the treatment of ependymoma on an individual basis. Incorporating and validating surrogate immunohistochemical markers for different molecular subgroups would ensure faster adaptation of molecular classification into routine clinical practice. Understanding molecular biology and exploring novel targets for treatment is bound to change the management of ependymoma in the near future.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst
2001; 17 (9): 503–11.
Jain A, Sharma MC, Suri V, Kale SS, Mahapatra AK, Tatke M, Chacko G, Pathak A, Santosh V, Nair P, Husain N, Sarkar C. Spectrum of pediatric brain tumors in India: a multi-institutional study. Neurol India
2011; 59 (2): 208–11.
Jalali R, Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol
2008; 87 (1): 111–4.
Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR. Adult ependymal tumors: prognosis and the M. D. Anderson cancer center experience. Neuro Oncol
2010; 12 (8): 862–70.
Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol
2009; 10 (3): 258–66.
Rogers L, Pueschel J, Spetzler R, Shapiro W, Coons S, Thomas T, Speiser B. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg
2005; 102 (4): 629–36.
Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic Impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol
2016; 34 (21): 2468–77.
Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC, Edan C, Chastagner P, Kalifa C; French Society of Pediatric Oncology. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French society of pediatric oncology. J Clin Oncol
2001; 19 (5): 1288–96.
Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, Cox T, Chong WK, Campbell RH, Bailey CC, Gattamaneni R, Picton S, Thorpe N, Mallucci C, English MW, Punt JA, Walker DA, Ellison DW, Machin D; Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol
2007; 8 (8): 696–705.
McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer
2009; 52 (1): 65–9.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol
2007; 114 (2): 97–109.
Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, Frappaz D, Massimino M, Grill J, Boyett JM, Grundy RG. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed
2011; 10: 7.
Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M, Pfister SM. Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups. Cancer Cell
2015; 27 (5): 728–43.
Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol
2017; 133 (1): 5–12.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol
2016; 131 (6): 803–20.
Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, Rusch MC, Chen K, Harris CC, Ding L, Holmfeldt L, Payne-Turner D, Fan X, Wei L, Zhao D, Obenauer JC, Naeve C, Mardis ER, Wilson RK, Downing JR, Zhang J. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods
2011; 8 (8): 652–4.
Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, Lee R, Tatevossian RG, Phoenix TN, Thiruvenkatam R, White E, Tang B, Orisme W, Gupta K, Rusch M, Chen X, Li Y, Nagahawhatte P, Hedlund E, Finkelstein D, Wu G, Shurtleff S, Easton J, Boggs K, Yergeau D, Vadodaria B, Mulder HL, Becksfort J, Gupta P, Huether R, Ma J, Song G, Gajjar A, Merchant T, Boop F, Smith AA, Ding L, Lu C, Ochoa K, Zhao D, Fulton RS, Fulton LL, Mardis ER, Wilson RK, Downing JR, Green DR, Zhang J, Ellison DW, Gilbertson RJ. C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma. Nature
2014; 506 (7489): 451–5.
Rogers HA, Kilday JP, Mayne C, Ward J, Adamowicz-Brice M, Schwalbe EC, Clifford SC, Coyle B, Grundy RG. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathol
2012; 123 (5): 711–25.
Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D, Sabari B, Margol AS, Panwalkar P, Parolia A, Pekmezci M, McEachin RC, Cieslik M, Tamrazi B, Garcia BA, La Rocca G, Santi M, Lewis PW, Hawkins C, Melnick A, David Allis C, Thompson CB, Chinnaiyan AM, Judkins AR, Venneti S. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med
2016; 8 (366): 366ra161.
Snider CA, Yang K, Mack SC, Suh JH, Chao ST, Merchant TE, Murphy ES. Impact of radiation therapy and extent of resection for ependymoma in young children: a population-based study. Pediatr Blood Cancer
2018; 65 (3): e26880.
Ramaswamy V, Taylor MD. Treatment implications of posterior fossa ependymoma subgroups. Chin J Cancer
2016; 35 (1): 93.
Tabori U, Wong V, Ma J, Shago M, Alon N, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C. Telomere maintenance and dysfunction predict recurrence in pediatric ependymoma. Br J Cancer
2008; 99 (7): 1129–35.
Zapotocky M, Ramaswamy V. Can telomerase activity be unleashed to refine prognosis within ependymoma subgroups? Neuro Oncol
2017; 19 (9): 1149–51.
Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H, Dieckmann K, Ambros IM, Ambros PF, Slavc I, Haberler C. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. Acta Neuropathol Commun
2016; 4 (1): 88.
Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, Mauguen A, Varlet P, Le Deley MC, Lowe J, Ellison DW, Gilbertson RJ, Coyle B, Grill J, Grundy RG. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the children's cancer leukaemia group (CCLG), Societe Francaise d'oncologie pediatrique (SFOP), and international society for pediatric oncology (SIOP). Clin Cancer Res
2012; 18 (7): 2001–11.
Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA, Boop FA, Gajjar A, Merchant TE, Ellison DW. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol
2012; 124 (2): 247–57.
Olsen TK, Gorunova L, Meling TR, Micci F, Scheie D, Due-Tønnessen B, Heim S, Brandal P. Genomic characterization of ependymomas reveals 6q loss as the most common aberration. Oncol Rep
2014; 32 (2): 483–90.
Ebert C, von Haken M, Meyer-Puttlitz B, Wiestler OD, Reifenberger G, Pietsch T, von Deimling A. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol
1999; 155 (2): 627–32.
Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res
2006; 12 (7 Pt 1): 2070–9.
Suzuki SO, Iwaki T. Amplification and overexpression of mdm2 gene in ependymomas. Mod Pathol
2000; 13 (5): 548–53.
Zakrzewska M, Fendler W, Zakrzewski K, Sikorska B, Grajkowska W, Dembowska-Bagińska B, Filipek I, Stefańczyk Ł, Liberski PP. Altered microRNA expression is associated with tumor grade, molecular background and outcome in childhood infratentorial ependymoma. PLoS One
2016; 11 (7): e0158464.
Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, Rajaram V, Bonaldo Mde F, Wang D, Goldman S, Tomita T, Soares MB. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One
2011; 6 (10): e25114.
Lourdusamy A, Rahman R, Smith S, Grundy R. MicroRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. Acta Neuropathol Commun
2015; 3: 26.
Wani K, Armstrong TS, Jones DT, Vera-Bolanos E, Witt H, Capper D, Pfister SM, Gilbertson RJ, Gilbert MR, Aldape K. Characterization of L1CAM as a clinical marker for the C11orf95-RELA fusion in supratentorial ependymomas. Neuro Oncol
2014; 16 (Suppl 5): v30.
Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro
and in vivo
high-throughput screen identifies treatment leads for ependymoma. Cancer Cell
2011; 20 (3): 384–99.
Tsangaris GT, Papathanasiou C, Adamopoulos PG, Scorilas A, Vorgias CE, Prodromou N, Stathopoulou FT, Stravopodis DJ, Anagnostopoulos AK. Pediatric ependymoma: a proteomics perspective. Cancer Genomics Proteomics
2017; 14 (2): 127–36.
Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase I study of 5-fluorouracil in children and young adultswith recurrent ependymoma. Neuro Oncol
2015; 17 (12): 1620–7.
Phi JH, Choi SA, Kim SK, Wang KC, Lee JY, Kim DG. Overcoming chemoresistance of pediatric ependymoma by inhibition of STAT3 signaling. Transl Oncol
2015; 8 (5): 376–86.
Li AM, Dunham C, Tabori U, Carret AS, McNeely PD, Johnston D, Lafay-Cousin L, Wilson B, Eisenstat DD, Jabado N, Zelcer S, Silva M, Scheinemann K, Fryer C, Hendson G, Fotovati A, Hawkins C, Yip S, Dunn SE, Hukin J. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian pediatric brain tumor consortium study. Cancer
2015; 121 (9): 1499–507.
Kings H, Chapman RJ, Mayne C, Rogers HA, Grundy RG. Investigation of the clinical potential of agents targeting epigenetic modifications in paediatricependymoma. Neuro Oncol
2015;17 (Suppl 8): viii8.
Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I, Lodrini M, Gröne HJ, Benner A, Brüstle O, Gilbertson RJ, von Deimling A, Kulozik AE, Pfister SM, Martin-Villalba A, Witt O. A novel human high-risk ependymoma stem cell model reveals the differentiation inducing potential of the histone deacetylase inhibitor vorinostat. Acta Neuropathol
2011; 122 (5): 637–50.
Wong VC, Morrison A, Tabori U, Hawkins CE. Telomerase inhibition as a novel therapy for pediatric ependymoma. Brain Pathol
2010; 20 (4): 780–6.
Servidei T, Meco D, Trivieri N, Patriarca V, Vellone VG, Zannoni GF, Lamorte G, Pallini R, Riccardi R. Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro
and in orthotopic mouse models. Int J Cancer
2012; 131 (5): E791–803.
Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC; Children's Oncology Group. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a children's oncology group study. J Clin Oncol
2005; 23 (25): 6172–80.
Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer
2008; 123 (1): 209–16.
Tzaridis T, Milde T, Pajtler KW, Bender S, Jones DT, Müller S, Wittmann A, Schlotter M, Kulozik AE, Lichter P, Peter Collins V, Witt O, Kool M, Korshunov A, Pfister SM, Witt H. Low-dose actinomycin-D treatment re-establishes the tumorsuppressive function of p53 in RELA-positive ependymoma. Oncotarget
2016; 7 (38): 61860–73.
Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res
2006; 34 (8): 2294–304.